Rogel Cancer Center: University of Michigan
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
305
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (267 trials with phase data)• Click on a phase to view related trials
Pilot Investigation of Dual Energy CT Imaging on an Online Adaptive Radiation Therapy System
- Conditions
- Malignant Pelvic NeoplasmGenitourinary System Carcinoma
- First Posted Date
- 2025-10-21
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT07219134
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Electronic Health Record ReviewOther: Questionnaire Administration
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-11-12
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT07158021
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
- Conditions
- Neuroendocrine Tumor
- Interventions
- Procedure: Computed TomographyDrug: Gallium Ga 68-DOTA-FAPI-04Procedure: Positron Emission Tomography
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT07132645
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
- Conditions
- Oral Cavity Squamous Cell CarcinomaStage I Lip and Oral Cavity Cancer AJCC v8Stage II Lip and Oral Cavity Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage IVA Lip and Oral Cavity Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Modified Barium SwallowProcedure: Positron Emission TomographyOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Sentinel Lymph Node BiopsyProcedure: Single Photon Emission Computed TomographyRadiation: Technetium Tc 99m-labeled TilmanoceptOther: Technetium Tc-99m Sulfur Colloid
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT07121595
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07096999
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 61
- Next
News
Genprex's Reqorsa Gene Therapy Shows 79% Tumor Reduction in ALK-Positive Lung Cancer Preclinical Study
Genprex's Reqorsa gene therapy demonstrated a 79% tumor reduction in ALK-positive non-small cell lung cancer models during preclinical studies presented at the 2025 AACR-NCI-EROTC Conference.